Funding for this research was provided by:
U.S. Department of Veterans Affairs (I01BX002234, I01BX001660)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (P50 AR060772-6)
CymaBay Therapeutics Inc
Received: 9 May 2018
Accepted: 14 August 2018
First Online: 6 September 2018
: The handing of mice and experimental procedures were in accordance with requirements of the Institutional Animal Care and Use Committee and this study was granted permission by the CymaBay Research Oversight Committee.
: Not applicable.
: RT has received research support jointly from Ardea/Astra-Zeneca and Ironwood, and has received payment as a consultant to SOBI, Selecta, and Horizon, and has a consulting agreement with CymaBay Therapeutics, Inc. RLB has received research funding from by CymaBay Therapeutics, Inc. The remaining authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.